natgillin/translations-raw huggingface dataset:
Tardive dyskinesia Parkinsonism Movement disorder
tardivna diskinezija, parkinsonizam, poremećaj kretanja,
tardive dyskinesia, convulsiond, syncope, psychomotor hyperactivity, dizziness postural,
tardivna diskinezija, konvulzijed, sinkopa, psihomotorna hiperaktivnost, posturalna omaglica, poremećaj pozornosti, disartrija, disgeuzija, hipoestezija, parestezija
tardive dyskinesia, convulsione, syncope, psychomotor hyperactivity, dizziness postural, disturbance in attention, dysarthria, dysgeusia, hypoaesthesia, paresthaesia
tardivna diskinezija, konvulzijee, sinkopa, psihomotorna hiperaktivnost, posturalna omaglica,
tardive dyskinesia, convulsione, syncope, psychomotor hyperactivity, dizziness postural, disturbance in attention, dysarthria, dysgeusia, hypoaesthesia, paresthaesia
tardivna diskinezija, konvulzijee, sinkopa, psihomotorna hiperaktivnost, posturalna omaglica, poremećaj pozornosti, disartrija, disgeuzija, hipoestezija, parestezija
Tardive dyskinesia11
Tardivna
Tardive dyskinesia11
Tardivna diskinezija
Tardive dyskinesia11
tardivna diskinezija11 amnezija9
Target
Učestalost
target 3 mg/kg bodyweight/day
Ciljna doza 3 mg/kg tjelesne mase/danu
Target Factor VIII Trough Activity (Units per dL or % of normal)
Najniža ciljna aktivnost faktora VIII (jedinice po dl ili % normale)
Target Hb
ciljni Hb
Target Hb (10 - 12 g/dl)
ciljna vrijednost Hb (10 - 12 g/dl)
Target oral olanzapine dose
Ciljna doza oralnog olanzapina
Target organs for neoplastic changes were the kidneys, urinary bladder, urethra, preputial and clitoral gland, small intestine, parathyroid glands, adrenal glands and non- glandular stomach.
Ciljni organi neoplastičkih promjena bili su bubrezi, mokraćni mjehur, uretra, žlijezda prepucija i klitorisa, tanko crijevo, paratireoidne žlijezde, nadbubrežne žlijezde i ne-žljezdani dio želuca.
Target organs for neoplastic changes were the kidneys, urinary bladder, urethra, preputial and clitoral gland, small intestine, parathyroid glands, adrenal glands and non- glandular stomach.
Ciljni organi neoplastičkih promjena bili su bubrezi, mokraćni mjehur, uretra, žlijezda prepucija i klitorisa, tanko crijevo, paratireoidne žlijezde, nadbubrežne žlijezde i ne-žljezdani želudac.
Target organs for neoplastic changes were the kidneys, urinary bladder, urethra, preputial and clitoral gland, small intestine, parathyroid glands, adrenal glands and non- glandular stomach.
Ciljni organi neoplastičkih promjena bili su bubrezi, mokraćni mjehur, uretra, žlijezda prepucija i klitorisa, tanko crijevo, paratireoidne žlijezde, nadbubrežne žlijezde i nežljezdani dio želuca.
Target platelet count was  90,000/µl for ENABLE 1 and  100,000/µl for ENABLE 2.
Ciljni broj trombocita bio je  90 000/µl u ENABLE 1 i  100 000/µl u ENABLE 2.
TARGET SPECIES
CILJNA VRSTA ŽIVOTINJA
TARGET SPECIES
KARENCIJA
Target Species Route of
Ciljne vrste životinja
Target tissue(s)
Ciljno tkivo
Target tumours were histologically confirmed single primary superficial basal cell carcinomas with a minimum size of 0.5 cm2 and a maximum diameter of 2 cm.
Ciljni tumor bio je histološki potvrđen pojedinačni primarni površinski bazeocelularni karcinom najmanje veličine od 0,5 cm2 i najvećega promjera od 2 cm.
Target-based mutations generated in preclinical studies lead to 8- to 133-fold increases in bedaquiline MIC, resulting in MICs ranging from 0.25 to 4.0 mg/l.
Ciljane mutacije razvijene u pretkliničkim ispitivanjima dovele su do od 8 do 133 puta većeg povećanja MIC–ova bedakilina, što je rezultiralo MIC-ovima u rasponu od 0,25 do 4,0 mg/l.
Targretin 75 mg soft capsules Bexarotene
Targretin 75 mg meke kapsule beksaroten
Targretin capsules should not be used in children or adolescents.
Targretin kapsule ne smiju se primjenjivati u djece i adolescenata.
Targretin contains a small amount of sorbitol (a type of sugar).
Targretin sadrži malu količinu sorbitola (vrsta šećera).
Targretin contains sorbitol and butylated hydroxyanisole
Targretin sadrži sorbitol i butilhidroksianizol
Targretin is not recommended in children (aged below 18 years).
Targretin se ne preporučuje u djece (u dobi do 18 godina).
Tartaric acid
tartaratna kiselina
Tartaric acid (E334) Mannitol (E421) Hydrochloric acid (E507) Sodium hydroxide
tartaratna kiselina (E334) manitol (E421) kloridna kiselina (E507) natrijev hidroksid
Tartaric acid (E334) Mannitol (E421) Hydrochloric acid(E507) Sodium hydroxide
tartaratna kiselina (E334) manitol (E421) kloridna kiselina (E507) natrijev hidroksid
tartaric acid (E334), mannitol (E421), hydrochloric acid (E507), sodium hydroxide.
Tartaratna kiselina (E334), manitol (E421), kloridna kiselina (E507), natrijev hidroksid.
tartaric acid (E334), mannitol (E421), hydrochloric acid (E507), sodium hydroxide.
Tartaratna kiselina (E334),manitol (E421), kloridna kiselina (E507), natrijev hidroksid.
Tartaric acid Ethylcellulose Hypromellose
tartaratna kiselina etilceluloza hipromeloza
tarting
(MMN)
tarting dose for adults: 3 to 6 tablets daily, in separated doses, with or immediately after main meals of the day.
početna doza za odrasle: 3 do 6 tableta dnevno u podijeljenim dozama uz glavne dnevne obroke ili odmah nakon njih.
tarting dose: 2 g/kg bw
početna doza: 2 g/kg TT
Tasermity 800 mg film-coated tablets
Tasermity 800 mg filmom obložene tablete
Tasermity 800 mg film-coated tablets sevelamer hydrochloride
Tasermity 800 mg filmom obložene tablete sevelamerklorid
Tasermity may be used with other medicines which include calcium or vitamin D supplements to control the development of renal bone disease.
Tasermity se može primijeniti uz druge lijekove koji uključuju nadomjestke kalcija ili vitamina D radi kontrole razvoja bubrežne osteodistrofije.
Tasermity should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Tasermity se smije koristiti s drugim terapijama poput dodataka kalcija i vitamina D kako bi se spriječio razvoj bolesti kosti.
Tasermity should not be taken at the same time as ciprofloxacin (an antibiotic).
Tasermity se ne bi smio uzimati istodobno s ciprofloksacinom (antibiotik).
Tasigna (nilotinib) 300 mg twice daily n=282 (%)
Tasigna (nilotinib) 300 mg dva puta na dan n=282 (%)
Tasigna (nilotinib) 400 mg twice daily n=281 (%)
Tasigna (nilotinib) 400 mg dva puta na dan n=281 (%)
Tasigna 150 mg hard capsules
Tasigna 150 mg tvrde kapsule nilotinib
Tasigna 150 mg hard capsules Nilotinib
Tasigna 150 mg tvrde kapsule nilotinib
Tasigna 200 mg hard capsules
Tasigna 200 mg tvrde kapsule nilotinib
Tasigna 200 mg hard capsules Nilotinib
Tasigna 200 mg tvrde kapsule nilotinib
Tasigna 300 mg twice daily (n = 282)
Tasigna 300 mg 2xdan (n = 282)
Tasigna 400 mg twice daily (n = 281)
Tasigna 400 mg 2xdan (n = 281)
Tasigna can be used by people aged 65 years and over at the same dose as for other adults.
Tasignu mogu uzimati osobe u dobi od 65 godina i više u istoj dozi kao ostale odrasle osobe.
Tasigna has been shown to prolong cardiac ventricular repolarisation as measured by the QT interval on the surface ECG in a concentration-dependent manner.
Pokazalo se da Tasigna, ovisno o koncentraciji, produžava repolarizaciju srčanih klijetki što se očituje produženim QT intervalom na standardnom EKG-u.
Tasigna is a medicine containing an active substance called nilotinib.
Tasigna je lijek koji sadrži djelatnu tvar zvanu nilotinib.
Tasigna is also available in multipacks of:
Tasigna je također dostupna u višestrukim pakiranjima od:
Tasigna is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase.
Tasigna je indicirana za liječenje odraslih bolesnika s novodijagnosticiranom kroničnom mijeloičnom leukemijom (KML) u kroničnoj fazi s pozitivnim Philadelphia kromosomom.
Tasigna is indicated for the treatment of adult patients with: newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.
Tasigna je indicirana za liječenje odraslih bolesnika: s novodijagnosticiranom kroničnom mijeloičnom leukemijom (KML) u kroničnoj fazi s pozitivnim Philadelphia kromosomom, u kroničnoj i ubrzanoj fazi KML-a s pozitivnim Philadelphia kromosomom s rezistencijom ili intolerancijom na prethodno liječenje, uključujući imatinib.
Tasigna is not recommended during pregnancy unless clearly necessary.
Tasigna se ne preporučuje tijekom trudnoće, osim ako je neophodno potrebno.
Tasigna is supplied as hard capsules.
Tasigna je dostupna u obliku tvrdih kapsula.
Tasigna is used in patients with newly diagnosed CML or in patients with CML who are no longer benefiting from previous treatment including imatinib.
Tasigna se primjenjuje u bolesnika s novodijagnosticiranim KML-om ili u bolesnika s KML-om u kojih je prethodno liječenje, uključujući imatinib, bezuspješno.
Tasigna is used in patients with newly diagnosed CML.
Tasigna se primjenjuje u bolesnika s novodijagnosticiranim KML-om.
Tasigna may interfere with some other medicines.
Tasigna može ući u interakciju s drugim lijekovima.
Tasigna may need to be temporarily withheld and/or dose reduced for haematological toxicities (neutropenia, thrombocytopenia) that are not related to the underlying leukaemia (see Table 1).
Primjena Tasigne može se privremeno prekinuti i/ili se može smanjiti doza pri pojavi hematološke toksičnosti (neutropenija, trombocitopenija) koja nije povezana s podležećom leukemijom (vidjeti Tablicu 1).
Tasigna should be used with caution in patients who have or who are at significant risk of developing prolongation of QTc, such as those: with congenital long QT prolongation
Tasigna se treba primjenjivati s oprezom u bolesnika s produženim QT intervalom ili sa značajnim rizikom od njegova razvoja, kao što su oni: s prirođenim sindromom produženog QT intervala.
Tasigna should not be used during breast-feeding.
Tasigna se ne bi trebala primjenjivati tijekom dojenja.
Tasigna with food and drink
Tasigna s hranom i pićem
Tasimelteon 20 mg
Tazimelteon 20 mg
Tasimelteon exposure decreased by approximately 40% in smokers, compared to non-smokers (see section 4.5).
Izloženost tazimelteonu u pušača smanjila se za otprilike 40 % u usporedbi s nepušačima (vidjeti dio 4.5.).
Tasimelteon has not been studied in patients with severe hepatic impairment (Child-Pugh Class C); therefore caution is recommended when prescribing HETLIOZ to patients with severe hepatic impairment.
Tazimelteon nije ispitan u bolesnika s teškim oštećenjem funkcije jetre (Child-Pugh stadij C); stoga je pri propisivanju lijeka HETLIOZ bolesnicima s teškim oštećenjem funkcije jetre potreban oprez.
Tasmar 100 mg (only applicable for the outer carton)
Tasmar 100 mg (primjenjivo samo na vanjsko pakiranje)
Tasmar has also been studied in a ‘switch’ study in 150 patients.
Tasmar je također ispitan u ispitivanju „prijelaza s jednog lijeka na drugi” u 150 bolesnika.
Tasmar has an effect on the symptoms of your Parkinson’s disease.
Tasmar ima učinke na simptome Parkinsonove bolesti.
Tasmar is a pale to light yellow, oval shaped, film-coated tablet.
Tasmar je blijeda do svijetložuta, ovalna filmom obložena tableta.
Tasmar is an orange yellow to brown yellow, oval shaped, film-coated tablet.
Tasmar je narančasto žuta do smeđe žuta, ovalna filmom obložena tableta.
Tasmar is contraindicated for patients with liver disease or increased liver enzymes.
Tasmar je kontraindiciran u bolesnika s bolešću jetre ili povišenim jetrenim enzimima.
Tasmar is indicated in combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-o-methyltransferase (COMT) inhibitors (see section 5.1).
Tasmar je indiciran u kombinaciji s levodopom/benzerazidom ili levodopom/karbidopom za primjenu u bolesnika s idiopatskom Parkinsonovom bolešću koja odgovara na levodopu i motoričkim fluktuacijama, a koji nisu odgovarali ili su intolerantni na druge inhibitore katehol-O-metiltransferaze (COMT, engl. catechol-o-methyltransferase) (vidjeti dio 5.1).
Tasmar is indicated in combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-O-methyltransferase COMT inhibitors (see section 5.1).
Tasmar je indiciran u kombinaciji s levodopom/benzerazidom ili levodopom/karbidopom za primjenu u bolesnika s idiopatskom Parkinsonovom bolešću koja odgovara na levodopu i motoričkim fluktuacijama, a koji nisu odgovarali ili su intolerantni na druge inhibitore katehol-O-metiltransferaze (COMT, engl. catechol-O-methyltransferase) (vidjeti dio 5.1).
Tasmar is not recommended for use in children below the age of 18 due to insufficient data on safety or efficacy.
Ne preporučuje se primjena Tasmara u djece mlađe od 18 godina zbog nedostatka podataka o sigurnosti i djelotvornosti.
Tasmar is used to treat patients with Parkinson’s disease.
Tasmar se koristi za liječenje bolesnika oboljelih od Parkinsonove bolesti.
Tasmar is used together with other standard treatments for Parkinson’s disease (either a combination of levodopa and benserazide or a combination of levodopa and carbidopa) when the patients have ‘fluctuations’ towards the end of the period between two doses of their standard combination.
Tasmar se koristi zajedno s drugim standardnim liječenjima za Parkinsonovu bolest (bilo kombinacijom levodopa i benserazida ili kombinacijom levodopa i karbidopa) u slučajevima kada bolesnici imaju „fluktuacije” prema kraju razdoblja između dvije doze svoje standardne kombinacije.
Tasmar is used when all other alternative medicines cannot stabilise your Parkinson’s disease.
Tasmar se primjenjuje kada svi drugi lijekovi ne mogu stabilizirati Parkinsonovu bolest.
Tasmar must also not be used in patients who are being treated with medicines known as non- selective monoamine oxidase (MAO) inhibitors.
Tasmar se također ne smije koristiti u bolesnika koji su liječeni lijekovima poznatima kao inhibitorima neselektivne monoamino oksidaze (MAO).
Tasmar therapy should only be initiated by physicians experienced in the management of advanced Parkinson’s disease, to ensure an appropriate risk-benefit assessment.
Terapiju Tasmarom trebaju započeti jedino liječnici iskusnici u zbrinjavanju uznapredovale Parkinsonove bolesti, kako bi osigurali odgovarajuću procjenu rizika i koristi.
Tasmar treatment should only be prescribed and supervised by a doctor who has experience in the management of advanced Parkinson’s disease.
Liječenje lijekom Tasmar treba propisati i nadzirati samo liječnik iskusan u zbrinjavanju i upravljanju uznapredovalom Parkinsonovom bolesti.
Tasmar used with your other Parkinson medicines can cause excessive drowsiness (somnolence) and sudden sleep onset episodes (you may suddenly fall asleep).
Tasmar primijenjen s drugim lijekovima za Parkinsonovu bolest može prouzročiti prekomjernu omamljenost (somnolenciju) i epizode iznenadnog nastupa sna (možete iznenada zaspati).
Tasmar, as a COMT inhibitor, is known to increase the bioavailability of the co-adminstered levodopa.
Poznato je da Tasmar, kao COMT inhibitor, povećava bioraspoloživost istodobno primjenjivane levodope.
taste abnormalities
poremećaji okusa
Taste alteration (dysgeusia)
Promjene u osjetu okusa (disgeuzija).
Taste change
promjena okusa
Taste changes, such as an unpleasant taste in the mouth.
Promjene u osjetu okusa, poput neugodnog okusa u ustima.
Taste changes.
promjene okusa
taste disorders
poremećaj osjeta okusa
Taste disorders
poremećaji okusa
Taste disturbance
poremećaj osjeta okusa
taste disturbance nausea (feeling sick)
poremećaj okusa mučnina
taste disturbance or loss of taste
poremećaj ili gubitak okusa
taste disturbance,
poremećaj okusa
Taste disturbances
lučajevi s fatalnim
taste disturbances
poremećaj osjeta okusa
taste disturbances
poremećaji osjeta okusa
taste disturbances sneezing
poremećaj osjeta okusa kihanje
taste disturbances,
poremećaji okusa,
taste disturbances,
poremećaji osjeta okusa,
taste disturbances, feeling sick (nausea), mouth ulcers, being sick (vomiting), loss of appetite
promjena osjeta okusa, mučnina, ranice u ustima, povraćanje, gubitak apetita
Taste disturbances, paraesthesia, headache, somnolence
Poremećaji osjeta okusa, parestezija, glavobolja, somnolencija
Taste disturbances.
poremećaji okusa;
Taste disturbance§ Dizziness
poremećaj osjeta okusa§ omaglica
taste problems – such as changes in the way things taste
tegobe s osjetom okusa – poput promjena u okusu
tasvir
CYP3A4
tasvir
virom
tatins (e.g. rosuvastatin) anti-viral medicines (e.g. oseltamivir, tenofovir, ganciclovir, adefovir, cidofovir, lamivudine, zidovudine, zalcitabine)
tatine (npr. rosuvastatin) antivursne lijekove (npr. oseltamivir, tenofovir, ganciklovir, adefovir, cidofovir, lamivudin, zidovudin, zalcitabin)
tatins (simvastatin and atorvastatin, both used to reduce the amount of cholesterol in blood).
tatini (simvastatin i atorvastatin, oba se koriste za smanjenje količine kolesterola u krvi).
tatins (such as simvastatin, lovastatin, atorvastatin, rosuvastatin, or pravastatin) (for reducing the cholesterol in your blood);
tatine (kao što su simvastatin, lovastatin, atorvastatin, rosuvastatin ili pravastatin) (za snižavanje razine kolesterola u krvi),
tatins such as atorvastatin, fluvastatin, pitavastatin, lovastatin (used to lower blood cholesterol)
tatini, primjerice atorvastatin, fluvastatin, pitavastatin, lovastatin (koriste se za smanjivanje kolesterola u krvi)
tatins used to treat high cholesterol.
tatine koji se primjenjuju za liječenje visokog kolesterola.
tatins – simvastatin or lovastatin
tatine – simvastatin ili lovastatin
tatins, for example simvastatin, pravastatin – used to lower blood cholesterol levels
tatini, na primjer simvastain, pravastatin – koriste se za snižavanje razine kolesterola u krvi
Taupe
ivkasto smeđa
Taupe
Sivkasto smeđa
TAUSSIG is an ongoing multicentre, open-label, 5-year extension study to assess the long-term safety and efficacy of Repatha, as an adjunct to other lipid lowering therapies, in patients with severe familial hypercholesterolaemia, including homozygous familial hypercholesterolaemia.
TAUSSIG je multicentrični, otvoreni, 5-godišnji produžetak ispitivanja u tijeku, za procjenu dugoročne sigurnosti i djelotvornosti lijeka Repatha kao dodatka ostalim terapijama za snižavanja lipida, u bolesnika s teškom obiteljskom hiperkolesterolemijom, uključujući homozigotnu obiteljsku hiperkolesterolemiju.
Taxespira 120 mg/6 ml concentrate for solution for infusion Docetaxel
Taxespira 120 mg/6 ml koncentrat za otopinu za infuziju docetaksel
Taxespira 120 mg/6 ml concentrate for solution for infusion Docetaxel
Taxespira 120 mg/6 ml koncentrat za otopinu za infuziju docetaksel i.v.
Taxespira 140 mg/7 ml concentrate for solution for infusion Docetaxel
Taxespira 140 mg/7 ml koncentrat za otopinu za infuziju docetaksel
Taxespira 140 mg/7 ml concentrate for solution for infusion Docetaxel
Taxespira 140 mg/7 ml koncentrat za otopinu za infuziju docetaksel i.v.
Taxespira 160 mg/8 ml concentrate for solution for infusion Docetaxel
Taxespira 160 mg/8 ml koncentrat za otopinu za infuziju docetaksel
Taxespira 160 mg/8 ml concentrate for solution for infusion Docetaxel
Taxespira 160 mg/8 ml koncentrat za otopinu za infuziju docetaksel i.v.
Taxespira 20 mg/1 ml concentrate for solution for infusion Docetaxel
Taxespira 20 mg/1 ml koncentrat za otopinu za infuziju docetaksel
Taxespira 20 mg/1 ml concentrate for solution for infusion Docetaxel
Taxespira 20 mg/1 ml koncentrat za otopinu za infuziju docetaksel i.v.
Taxespira 80 mg/4 ml concentrate for solution for infusion Docetaxel
Taxespira 80 mg/4 ml koncentrat za otopinu za infuziju docetaksel
Taxespira 80 mg/4 ml concentrate for solution for infusion Docetaxel
Taxespira 80 mg/4 ml koncentrat za otopinu za infuziju docetaksel i.v.
Taxespira as single agent
Taxespira u monoterapiji
Taxespira concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Taxespira koncentrat za otopinu za infuziju NE zahtijeva prethodno razrjeđivanje s otapalom te se može odmah dodati u infuzijsku otopinu.
Taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
Taxespira u kombinaciji s kapecitabinom indiciran je za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom dojke nakon neuspjeha terapije s drugim citostaticima.
Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Taxespira u kombinaciji sa cisplatinom i 5-fluorouracilom je indiciran za indukcijsko liječenje bolesnika s lokalno uznapredovalim karcinomom skvamoznih stanica glave i vrata.
Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
Taxespira u kombinaciji s cisplatinom i 5-fluorouracilom je indiciran za liječenje bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja, koji nisu prethodno primali kemoterapiju za metastatsku bolest.
Taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.
Taxespira u kombinaciji s cisplatinom indiciran je za liječenje bolesnika s neoperabilnim, lokalno uznapredovalim ili metastatskim karcinomom nemalih stanica pluća, koji nisu ranije primali kemoterapiju za tu bolest.
Taxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:
Taxespira u kombinaciji s doksorubicinom i ciklofosfamidom indiciran je za adjuvantno liječenje bolesnika s:
Taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.
Taxespira u kombinaciji s doksorubicinom indiciran je za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom dojke koji nisu ranije liječeni citostaticima za tu bolest.
Taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.
Taxespira u kombinaciji s prednizonom ili prednizolonom indiciran je za liječenje bolesnika s metastatskim karcinomom prostate refraktornim na hormonsko liječenje.
Taxespira in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.
Taxespira u kombinaciji s trastuzumabom indiciran je za liječenje bolesnika s metastatskim karcinomom dojke i prekomjerno izraženim HER2, koji nisu ranije primali kemoterapiju za metastatsku bolest.
Taxespira is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.
Taxespira je indiciran za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom nemalih stanica pluća nakon neuspjeha prethodne kemoterapije.
Taxespira is used with prednisone or prednisolone (anti-inflammatory medicines); gastric adenocarcinoma (a type of stomach cancer) in patients who have not yet received any treatment for their cancer.
Taxespira u kombinaciji s derivatima platine u bolesnika koji nisu ranije primali kemoterapiju
Taxespira was administered as a 1-hour infusion, all other medicinal products were given intravenously on day 1 every three weeks.
Taxespira se primjenjivao u obliku jednosatne infuzije, a svi ostali lijekovi davali su se intravenski na dan 1 svaka tri tjedna.